Analytical Data
-
Gene name
IL36RN
- Application
-
Alternative Names
IL36RN；FIL1D；IL1F5；IL1HY1；Interleukin-36 receptor antagonist Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBH0
-
Expression Region
2-155aa
-
AA Sequence
VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAEKVIKGEE ISVVPN RALD ASLSPVILGV QGGSQCLSCG TEKGPILKLE PVNIMELYLG A KESKSFTFY RRDMGLTSSF ESAAYPGWFL CTSPEADQPV RLTQIPE DPA WDAPITDFYF QQCD
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL36RN, also known as Interleukin-36 receptor antagonist, is a crucial protein involved in the regulation of the immune response, particularly within the context of inflammatory skin diseases and other autoimmune conditions. Research has shown that IL36RN plays a pivotal role in inhibiting the pro-inflammatory cytokine signaling mediated by IL-36 family members, which are known to contribute to the pathogenesis of various inflammatory disorders, such as psoriasis and atopic dermatitis. Mutations in the IL36RN gene have been linked to enhanced inflammatory responses, leading to the development of generalized pustular psoriasis and other related syndromes. As a result, understanding the mechanisms by which IL36RN functions has significant implications for therapeutic interventions. Recombinant IL36RN protein is being studied for its potential to restore immune balance and alleviate chronic inflammation, thereby providing a novel therapeutic avenue. The development of recombinant forms of this protein allows for detailed functional studies and may contribute to the design of targeted treatments aimed at modulating the immune response in patients suffering from IL-36 driven diseases. This ongoing research highlights the importance of IL36RN not only as a pivotal player in the immune system but also as a promising target for innovative therapies in the management of immune-mediated inflammatory conditions.
